Harnessing $ NAD^{+} $ Metabolism as Therapy for Cardiometabolic Diseases
Purpose of the Review This review summarizes current understanding on the roles of nicotinamide adenine dinucleotide ($ NAD^{+} $) metabolism in the pathogeneses and treatment development of metabolic and cardiac diseases. Recent Findings $ NAD^{+} $ was identified as a redox cofactor in metabolism and a co-substrate for a wide range of $ NAD^{+} $-dependent enzymes. $ NAD^{+} $ redox imbalance and depletion are associated with many pathologies where metabolism plays a key role, for example cardiometabolic diseases. This review is to delineate the current knowledge about harnessing $ NAD^{+} $ metabolism as potential therapy for cardiometabolic diseases. The review has summarized how $ NAD^{+} $ redox imbalance and depletion contribute to the pathogeneses of cardiometabolic diseases. Therapeutic evidence involving activation of $ NAD^{+} $ synthesis in pre-clinical and clinical studies was discussed. Summary While activation of $ NAD^{+} $ synthesis shows great promise for therapy, the field of $ NAD^{+} $ metabolism is rapidly evolving. Therefore, it is expected that new mechanisms will be discovered as therapeutic targets for cardiometabolic diseases..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Current heart failure reports - 19(2022), 4 vom: 13. Mai, Seite 157-169 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chakraborty, Akash [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Cardiometabolic diseases |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s11897-022-00550-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2079238485 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2079238485 | ||
| 003 | DE-627 | ||
| 005 | 20230509132705.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11897-022-00550-5 |2 doi | |
| 035 | |a (DE-627)OLC2079238485 | ||
| 035 | |a (DE-He213)s11897-022-00550-5-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Chakraborty, Akash |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Harnessing $ NAD^{+} $ Metabolism as Therapy for Cardiometabolic Diseases |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 | ||
| 520 | |a Purpose of the Review This review summarizes current understanding on the roles of nicotinamide adenine dinucleotide ($ NAD^{+} $) metabolism in the pathogeneses and treatment development of metabolic and cardiac diseases. Recent Findings $ NAD^{+} $ was identified as a redox cofactor in metabolism and a co-substrate for a wide range of $ NAD^{+} $-dependent enzymes. $ NAD^{+} $ redox imbalance and depletion are associated with many pathologies where metabolism plays a key role, for example cardiometabolic diseases. This review is to delineate the current knowledge about harnessing $ NAD^{+} $ metabolism as potential therapy for cardiometabolic diseases. The review has summarized how $ NAD^{+} $ redox imbalance and depletion contribute to the pathogeneses of cardiometabolic diseases. Therapeutic evidence involving activation of $ NAD^{+} $ synthesis in pre-clinical and clinical studies was discussed. Summary While activation of $ NAD^{+} $ synthesis shows great promise for therapy, the field of $ NAD^{+} $ metabolism is rapidly evolving. Therefore, it is expected that new mechanisms will be discovered as therapeutic targets for cardiometabolic diseases. | ||
| 650 | 4 | |a NAD | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a Cardiometabolic diseases | |
| 650 | 4 | |a Redox balance | |
| 650 | 4 | |a Heart failure | |
| 700 | 1 | |a Minor, Keaton E. |4 aut | |
| 700 | 1 | |a Nizami, Hina Lateef |4 aut | |
| 700 | 1 | |a Chiao, Ying Ann |4 aut | |
| 700 | 1 | |a Lee, Chi Fung |0 (orcid)0000-0002-5395-6925 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current heart failure reports |d Springer US, 2004 |g 19(2022), 4 vom: 13. Mai, Seite 157-169 |w (DE-627)390611905 |w (DE-600)2151202-4 |x 1546-9530 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2022 |g number:4 |g day:13 |g month:05 |g pages:157-169 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11897-022-00550-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2022 |e 4 |b 13 |c 05 |h 157-169 | ||